Evidence map›Paper›PMID 41559328›Full record

Trial reportAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026

Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial.

Jing Wang, Yue Qiao, Sijie Li, Chuanhui Li, Chuanjie Wu, Xiaojun Hao, Haiqing Song, Qingfeng Ma, Xunming Ji, Longfei Wu and 1 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04491695 (Safety and Efficacy of Tirofiban in Preventing Neurological Deterioration of Patients With Acute Ischemic Stroke), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04491695 phase2 / phase3unknown statusnot on this map

Safety and Efficacy of Tirofiban in Preventing Neurological Deterioration of Patients With Acute Ischemic Stroke: A Randomized Controlled Trial

TypeinterventionalSponsorCapital Medical UniversityRan2020 to 2023Enrolled420ConditionsAcute StrokeArmsTirofiban Hydrochloride, Oral antiplatelet
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jing Wang *Department of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Yue Qiao *Department of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Sijie LiDepartment of Emergency, Xuanwu Hospital Capital Medical University, Beijing, China.
Chuanhui LiDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Chuanjie WuDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Xiaojun HaoDepartment of Neurology, Ordos Central Hospital, Inner Mongolia, China.
Haiqing SongDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Qingfeng MaDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Xunming JiDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China.
Longfei WuDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. wlf_713@163.com.
Wenbo ZhaoDepartment of Neurology, Xuanwu Hospital Capital Medical University, No. 45, Changchun Street, Xicheng District, Beijing, 100053, China. zhaowb@xwh.ccmu.edu.cn.

Funding

Beijing Natural Science Fund for Outstanding Young Scholars JQ22020National Natural Science Fund of China 82422024
6 · The paper itself

Abstract

backgroundEarly neurological deterioration (END) in patients with acute ischemic stroke (AIS) is a common phenomenon strongly associated with unfavorable outcomes. The TREND trial (NCT04491695) demonstrates the efficacy of intravenous tirofiban compared to oral aspirin in preventing END.

aimsThe purpose of this study was to explore whether prior antiplatelet therapy (APT) affected the therapeutic effects of tirofiban.

methodsThis prespecified post hoc analysis of the TREND trial stratified patients by prior antiplatelet use. The primary outcome was END

resultsOverall, 425 patients with AIS were analyzed, including 143 (33.6%) and 282 (66.4%) with and without prior APT, respectively. In patients without prior APT, tirofiban significantly reduced the risk of END

conclusionsIntravenous tirofiban significantly reduced the risk of END compared with aspirin in patients with AIS who were not on prestroke APT. Although this benefit was attenuated in pretreated patients, tirofiban might maintain a consistent efficacy and safety profile irrespective of prior antiplatelet use.

Indexed as

Ischemic StrokePlatelet Aggregation InhibitorsStrokeTirofibanAdministration, IntravenousAgedAspirinFemaleHumansMaleMiddle AgedTreatment OutcomeAspirinPlatelet Aggregation InhibitorsTirofiban

Identifiers

PMID41559328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.